ADVERTISEMENT

Lymphoma, Myeloma & Prostate Cancer

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. 

BY ELIZABETH WHITTINGTON @eyoste
PUBLISHED FRIDAY, MARCH 13, 2009
Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.
The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with non-Hodgkin lymphoma and multiple myeloma who are undergoing a stem cell transplant. The injectable drug, given in combination with a growth factor called granulocyte-colony stimulating factor (G-CSF), boosts the number of stem cells in the blood, where they can be collected for transplantation.

In autologous stem cell transplantation, a patient’s stem cells are collected (called apheresis) before high-dose chemotherapy and/or radiation. The high-dose therapy kills cancer cells, but also destroys stem cells that develop into other blood cells. To counter this effect, patients are reinfused with the collected stem cells.

Typically, apheresis requires up to four hours over several days, but Mozobil appears to make the process faster and more successful. A study involving NHL patients found that in up to four apheresis attempts, 59 percent of patients taking G-CSF plus Mozobil had successful stem cell collections compared with 20 percent of patients receiving only G-CSF. Results were similar in a study with multiple myeloma patients. Adding Mozobil allowed patients to reach an adequate number of collected stem cells in a median of one day compared with four days using G-CSF alone. Side effects of Mozobil include fatigue, nausea, and diarrhea.

For more information, visit www.mozobil.com or call 877-466-9624 (site is owned by Genzyme, maker of Mozobil).

Degarelix, a type of hormonal therapy, was approved by the Food and Drug Administration for advanced hormone-dependent prostate cancer at the end of December. At press time, possible trade names were still being reviewed by the FDA.

Degarelix, an injectable gonadotrophin-releasing hormone (GnRH) blocker, reduces levels of testosterone, a hormone produced by the testes and adrenal glands that can drive the growth of some prostate cancers. This has been shown to lower prostate-specific antigen, a measure of the amount of prostate cancer.

The FDA based its approval on phase III studies that compared degarelix with another GnRH blocker called Lupron (leuprolide), a standard treatment for advanced prostate cancer. Degarelix came out on top in the studies, primarily because of the drug’s unique mechanism of action.

Degarelix works by binding to the receptors of the brain’s pituitary cells, blocking the production of luteinizing hormone (a hormone that stimulates the testes to produce testosterone). Patients taking degarelix do not experience the initial “flare” of hormone levels (and possible cancer growth) that is seen with other GnRH blockers such as Lupron.

Phase III studies have confirmed that degarelix suppresses testosterone levels and PSA faster than Lupron without causing the initial hormone flare and cancer growth. In a phase III study published in the British Journal of Urology International, 95 percent of patients taking degarelix achieved complete testosterone suppression on the third day of treatment compared with zero percent of patients taking Lupron. After two weeks, nearly 100 percent of degarelix patients had hormone suppression, while only 18 percent of patients on Lupron reached a comparable level.

Common side effects of degarelix, such as fatigue, weight gain, and hot flashes, were comparable to Lupron, although degarelix was associated with more injection-site skin reactions. For more information, visit www.prostatecancerliving.com (site is owned by Ferring Pharmaceuticals, maker of degarelix). 

Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.
ADVERTISEMENT
Related Articles
FDA Approves Zytiga Label Update for Use in Chemo-Naive Men with Metastatic Prostate Cancer
BY SILAS INMAN
The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Hitting Back at Hodgkin Lymphoma
In the ring, it's not about whether you win or lose; it's about never staying down and never giving up.
Juliana's Story
When my doctor told me that I had stage 4, grade 3a follicular lymphoma, I thought that it was impossible: I had firmly put cancer in my rear view mirror seven years prior. Yet here I was, hearing for the word “cancer” for the second time by the age of 26.
Making Sense of the Prostate Cancer Screening Debate
BY TONY BERBERABE, MPH
The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press.
AR-V7 and Response to Taxanes in Metastatic Hormone-Resistant Prostate Cancer
BY ANDREW J. ROTH
Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.
Related Videos
Dr. Adam Asch Encourages Lymphoma Patients to Fully Understand Their Diagnosis
Adam Asch, senior deputy director of Stephenson Cancer Center, gives advice to patients after they have been diagnosed with lymphoma.
Anne Quinn Young, of the MMRF, Discusses Immunotherapies Being Studied in Multiple Myeloma
Anne Quinn Young, of the Multiple Myeloma Research Foundation, discusses some of the antibodies that are being studied in multiple myeloma.
Myeloma Expert Brian Durie Discusses the ASPIRE Trial
Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.
Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers
Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.
MMRF’s CoMMpass Study Highlights and Moves Research of Myeloma Forward
Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$